Cargando…
COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review
BACKGROUND: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of infection. OBJECTIVE: To assess whether patients undergoing pharmacological treatment for IMID present higher risk of worse outcomes when diagnosed with COVID-19. DESIGN AND SETTING: Rapid systematic revi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Paulista de Medicina - APM
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685570/ https://www.ncbi.nlm.nih.gov/pubmed/33331606 http://dx.doi.org/10.1590/1516-3180.2020.0421.R2.10092020 |
_version_ | 1784835536024764416 |
---|---|
author | da Rocha, Aline Pereira Atallah, Álvaro Nagib Pinto, Ana Carolina Pereira Nunes Rocha-Filho, César Ramos Milby, Keilla Martins Civile, Vinicius Tassoni Carvas, Nelson Reis, Felipe Sebastião de Assis Ferla, Laura Jantsch Ramalho, Gabriel Sodré Trevisani, Giulia Fernandes Moça Puga, Maria Eduarda dos Santos Trevisani, Virgínia Fernandes Moça |
author_facet | da Rocha, Aline Pereira Atallah, Álvaro Nagib Pinto, Ana Carolina Pereira Nunes Rocha-Filho, César Ramos Milby, Keilla Martins Civile, Vinicius Tassoni Carvas, Nelson Reis, Felipe Sebastião de Assis Ferla, Laura Jantsch Ramalho, Gabriel Sodré Trevisani, Giulia Fernandes Moça Puga, Maria Eduarda dos Santos Trevisani, Virgínia Fernandes Moça |
author_sort | da Rocha, Aline Pereira |
collection | PubMed |
description | BACKGROUND: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of infection. OBJECTIVE: To assess whether patients undergoing pharmacological treatment for IMID present higher risk of worse outcomes when diagnosed with COVID-19. DESIGN AND SETTING: Rapid systematic review conducted in the medical school of the Federal University of São Paulo (SP), Brazil. METHODS: We searched CENTRAL, MEDLINE, EMBASE, LILACS, SCOPUS, Web of Science, L·OVE, ClinicalTrials.gov and WHO-ICTRP for studies evaluating patients diagnosed with COVID-19 who were undergoing pharmacological treatment for IMID. Two authors selected studies, extracted data and assessed risk of bias and certainty of evidence, following the Cochrane recommendations. RESULTS: We identified 1,498 references, from which one cohort study was included. This compared patients with and without rheumatic diseases (RD) who all had been diagnosed with COVID-19. Those with RD seemed to have higher chances of hospitalization and mortality, but no statistical difference was detected between the groups: hospitalization: odds ratio (OR) 1.17; 95% confidence interval (CI) 0.6 to 2.29; mortality rate: OR 1.53; 95% CI 0.33 to 7.11 (very low certainty of evidence). Patients with RD were three times more likely to require admission to intensive care units (ICUs), with invasive mechanical ventilation (IMV), than those without RD: OR 3.72; 95% CI 1.35 to 10.26 (for both outcomes; very low certainty of evidence). CONCLUSION: Patients undergoing pharmacological treatment for IMID seem to present higher chances of requiring admission to ICUs, with IMV. Additional high-quality studies are needed to analyze the effects of different treatments for IMID. |
format | Online Article Text |
id | pubmed-9685570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Associação Paulista de Medicina - APM |
record_format | MEDLINE/PubMed |
spelling | pubmed-96855702022-11-25 COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review da Rocha, Aline Pereira Atallah, Álvaro Nagib Pinto, Ana Carolina Pereira Nunes Rocha-Filho, César Ramos Milby, Keilla Martins Civile, Vinicius Tassoni Carvas, Nelson Reis, Felipe Sebastião de Assis Ferla, Laura Jantsch Ramalho, Gabriel Sodré Trevisani, Giulia Fernandes Moça Puga, Maria Eduarda dos Santos Trevisani, Virgínia Fernandes Moça Sao Paulo Med J Original Article BACKGROUND: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of infection. OBJECTIVE: To assess whether patients undergoing pharmacological treatment for IMID present higher risk of worse outcomes when diagnosed with COVID-19. DESIGN AND SETTING: Rapid systematic review conducted in the medical school of the Federal University of São Paulo (SP), Brazil. METHODS: We searched CENTRAL, MEDLINE, EMBASE, LILACS, SCOPUS, Web of Science, L·OVE, ClinicalTrials.gov and WHO-ICTRP for studies evaluating patients diagnosed with COVID-19 who were undergoing pharmacological treatment for IMID. Two authors selected studies, extracted data and assessed risk of bias and certainty of evidence, following the Cochrane recommendations. RESULTS: We identified 1,498 references, from which one cohort study was included. This compared patients with and without rheumatic diseases (RD) who all had been diagnosed with COVID-19. Those with RD seemed to have higher chances of hospitalization and mortality, but no statistical difference was detected between the groups: hospitalization: odds ratio (OR) 1.17; 95% confidence interval (CI) 0.6 to 2.29; mortality rate: OR 1.53; 95% CI 0.33 to 7.11 (very low certainty of evidence). Patients with RD were three times more likely to require admission to intensive care units (ICUs), with invasive mechanical ventilation (IMV), than those without RD: OR 3.72; 95% CI 1.35 to 10.26 (for both outcomes; very low certainty of evidence). CONCLUSION: Patients undergoing pharmacological treatment for IMID seem to present higher chances of requiring admission to ICUs, with IMV. Additional high-quality studies are needed to analyze the effects of different treatments for IMID. Associação Paulista de Medicina - APM 2020-12-14 /pmc/articles/PMC9685570/ /pubmed/33331606 http://dx.doi.org/10.1590/1516-3180.2020.0421.R2.10092020 Text en © 2022 by Associação Paulista de Medicina https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons license. |
spellingShingle | Original Article da Rocha, Aline Pereira Atallah, Álvaro Nagib Pinto, Ana Carolina Pereira Nunes Rocha-Filho, César Ramos Milby, Keilla Martins Civile, Vinicius Tassoni Carvas, Nelson Reis, Felipe Sebastião de Assis Ferla, Laura Jantsch Ramalho, Gabriel Sodré Trevisani, Giulia Fernandes Moça Puga, Maria Eduarda dos Santos Trevisani, Virgínia Fernandes Moça COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title | COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title_full | COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title_fullStr | COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title_full_unstemmed | COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title_short | COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
title_sort | covid-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685570/ https://www.ncbi.nlm.nih.gov/pubmed/33331606 http://dx.doi.org/10.1590/1516-3180.2020.0421.R2.10092020 |
work_keys_str_mv | AT darochaalinepereira covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT atallahalvaronagib covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT pintoanacarolinapereiranunes covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT rochafilhocesarramos covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT milbykeillamartins covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT civileviniciustassoni covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT carvasnelson covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT reisfelipesebastiaodeassis covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT ferlalaurajantsch covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT ramalhogabrielsodre covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT trevisanigiuliafernandesmoca covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT pugamariaeduardadossantos covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview AT trevisanivirginiafernandesmoca covid19andpatientswithimmunemediatedinflammatorydiseasesundergoingpharmacologicaltreatmentsarapidlivingsystematicreview |